Indira Gandhi Memorial Hospital

Indira Gandhi Memorial Hospital (IGMH) is the largest government-owned multi-specialty tertiary care facility in the Maldives, located in the capital city of Malé. Established on April 15, 1995, IGMH replaced the previous Central Hospital, which was later demolished to make way for another hospital. The hospital is dedicated to Indira Gandhi and serves as a significant healthcare provider in the region.

As a state-owned entity, IGMH operates under the Ministry of Health and is fully covered by the Aasandha social healthcare insurance scheme. The hospital offers a wide range of services across various departments, including Anesthesiology, Cardiology, Dentistry, Dermatology, Dietetics & Nutrition, Emergency & Trauma, Endocrinology, ENT, Gastroenterology, Gynaecological Oncology, Internal Medicine, Laboratory Medicine, Nephrology, Neurology, Neurosurgery, Obstetrics & Gynecology, Oncology, Ophthalmology, Oral and Maxillofacial Surgery, Orthopedics, Paediatrics, Paediatric Cardiology, Paediatric Neurology, Physiotherapy, Plastic & Reconstructive Surgery, Psychiatry, Pulmonology, Radiology, Rheumatology, Surgery, Surgical Oncology, Speech Therapy, and Urology. (igmh.gov.mv)

IGMH's distribution network primarily focuses on the procurement and distribution of pharmaceutical products essential for its diverse medical services. The hospital's logistics capabilities are designed to ensure the timely and efficient delivery of medical supplies to various departments, maintaining a continuous supply chain to meet patient care needs. While specific details about warehouse locations and geographic coverage are not publicly disclosed, IGMH's central location in Malé facilitates access to international shipping routes, enabling the importation of medical supplies from global suppliers.

In the Maldives' pharmaceutical supply chain, IGMH functions as a primary hospital supplier, directly importing and distributing pharmaceutical products necessary for its operations. The hospital's role is critical in ensuring the availability of essential medications and medical supplies, thereby supporting the healthcare needs of the population. IGMH's direct procurement from international suppliers underscores its pivotal position in the nation's healthcare infrastructure.

IGMH's pharmaceutical sourcing exhibits a high degree of concentration, with a total import value of $962,000 USD from India across 106 shipments, focusing exclusively on five oncology products. This concentrated sourcing strategy indicates a strategic choice to streamline procurement processes and maintain consistency in product quality. The exclusive reliance on a single supplier, NU Hospitals Private Limited, for all shipments suggests a stable and long-term relationship, potentially reducing procurement complexities and ensuring reliable supply. However, this single-source dependency also poses risks, such as vulnerability to supply chain disruptions or changes in supplier terms.

The resilience of IGMH's Indian supply chain appears robust, given the consistent procurement of finished pharmaceutical formulations from a single supplier, NU Hospitals Private Limited. The hospital's focus on a limited number of oncology products may enhance supply chain stability by simplifying logistics and inventory management. However, the lack of backup suppliers and limited formulation diversity could expose IGMH to risks if the primary supplier faces operational challenges or regulatory issues. Additionally, the hospital's reliance on a single shipping route for imports may increase exposure to logistical disruptions.

IGMH's concentrated sourcing strategy positions it to benefit from streamlined procurement processes and potentially favorable terms with its sole supplier. This approach may lead to cost efficiencies and consistent product quality. For Indian exporters, the hospital's exclusive relationship with NU Hospitals Private Limited presents an opportunity to explore alternative supply channels to IGMH, potentially diversifying the hospital's supplier base and mitigating risks associated with single-source dependency.

The Maldives Food and Drug Authority (MFDA) is the primary regulatory body overseeing the importation, manufacture, distribution, and sale of pharmaceuticals in the Maldives. The MFDA operates under the Ministry of Health and is responsible for ensuring that all medicinal products meet established safety, efficacy, and quality standards. The MFDA's regulations are designed to protect public health by regulating the pharmaceutical supply chain and ensuring that only approved and safe medications are available in the market. (maldivesvoice.mv)

Import licensing requirements in the Maldives stipulate that all medicine importers and sellers must be registered and licensed by the MFDA. Only drugs listed under the country's Approved Drug List are permitted for import and distribution. The MFDA recognizes Good Manufacturing Practice (GMP) certificates from reputable international standards, including EU GMP, WHO GMP, and PIC/S, ensuring that imported pharmaceuticals adhere to high-quality manufacturing standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the country. (maldivesvoice.mv)

Pharmaceutical products imported into the Maldives must undergo batch testing to ensure compliance with safety and efficacy standards. Stability requirements are enforced to guarantee that medications maintain their intended potency and safety throughout their shelf life. Labeling language requirements mandate that product information be provided in the local language, ensuring clear communication with consumers. Serialization mandates are implemented to enhance traceability and prevent counterfeit products from entering the market, thereby safeguarding public health.

Between 2024 and 2026, the Maldives Food and Drug Authority (MFDA) has intensified its regulatory oversight, particularly concerning the importation and sale of pharmaceuticals. The MFDA has launched investigations into unauthorized advertising and sale of medicines on social media platforms, emphasizing the need for all medicine importers and sellers to be registered and licensed. These measures aim to ensure that only approved and safe medications are available in the market, thereby protecting public health. (maldivesvoice.mv)

IGMH's focus on importing oncology products, specifically trastuzumab, osimertinib, pembrolizumab, cetuximab, and nivolumab, aligns with the hospital's strategic emphasis on providing comprehensive cancer care services. The high demand for these medications in the Maldives, driven by the prevalence of cancer cases and the hospital's commitment to offering advanced treatment options, necessitates a reliable supply of these critical drugs. The importation of these specific therapeutic areas underscores IGMH's dedication to enhancing patient outcomes through access to cutting-edge oncology treatments.

IGMH's sourcing strategy is centered on procuring finished pharmaceutical formulations, particularly in the oncology therapeutic area, from India. This approach ensures access to high-quality medications that meet international standards. The hospital's exclusive reliance on a single supplier, NU Hospitals Private Limited, reflects a strategic decision to maintain consistency in product quality and streamline procurement processes. However, this strategy also highlights the importance of establishing contingency plans to mitigate potential risks associated with single-source dependency.

Based on its product mix, IGMH serves the hospital segment of the Maldives market, focusing on providing specialized medical services, particularly in oncology, to both domestic and international patients. The hospital's strategic sourcing and procurement decisions are tailored to meet the specific needs of its patient population, ensuring the availability of essential medications and medical supplies to support its comprehensive healthcare services.

There is a realistic opportunity for new Indian suppliers to engage with IGMH, especially in the oncology therapeutic area. While the hospital currently relies on a single supplier, the high demand for specialized medications and the potential benefits of diversifying its supplier base present avenues for collaboration. Indian exporters can explore these opportunities by demonstrating compliance with MFDA regulations, ensuring product quality, and establishing reliable supply chains to meet IGMH's procurement standards.

Indian exporters seeking to supply pharmaceuticals to IGMH and the Maldives market must obtain the necessary import licenses and wholesale distribution authorizations from the Maldives Food and Drug Authority (MFDA). Products must adhere to recognized Good Manufacturing Practice (GMP) standards, such as EU GMP, WHO GMP, or PIC/S. Additionally, compliance with batch testing, stability requirements, labeling language mandates, and serialization regulations is essential to meet the MFDA's quality and safety standards.

To establish a relationship with IGMH, Indian exporters should initiate contact with the hospital's procurement department to understand specific product requirements and procurement processes. Participating in tenders and responding to Requests for Proposals (RFPs) issued by IGMH can provide opportunities for collaboration. Developing a comprehensive regulatory filing strategy that aligns with MFDA requirements, including obtaining necessary licenses and certifications, is crucial. Setting realistic timelines for product registration, quality assessments, and logistics planning will facilitate a smooth entry into the Maldives pharmaceutical market.